Department of Orthopaedics, Shanxian Central Hospital of Shandong Province , Heze, Shandong, P.R. China .
Cancer Biother Radiopharm. 2018 Nov;33(9):365-372. doi: 10.1089/cbr.2018.2503. Epub 2018 Jul 10.
The long noncoding RNA (LncRNA) SNHG7 (small nuclear RNA host gene 7) is a novel LncRNA and functions as an oncogene to promote tumor proliferation and inhibits apoptosis in many cancers. However, the role of SNHG7 in osteosarcoma (OS) remains to be further investigated. In this study, OS tissues and corresponding relative normal tissues (n = 30) were collected to determine the expression of SNHG7 in OS. The results indicated that high SNHG7 level in OS correlated with high Enneking stage, distant metastasis, and short overall survival time of OS patients. Moreover, miRNA-34a (miR-34a) is a classic tumor suppressor. Bioinformatic analysis predicted that SNHG7 harbored miR-34a binding sites, and the authors found that SNHG7 negatively correlated with miR-34a in OS tissues and the SNHG7 inhibition induced the restoration of miR-34a in OS cell lines MG63 and SaOS2, leading to the reactivation of miR-34a-mediated tumor suppression. Knockdown of SNHG7 in tumor cells significantly impaired the cell vitality, migration and invasion or TGF-β-induced epithelial-mesenchymal transition (EMT), induced apoptosis, and G1/S arrest via miR-34a. Mechanistically, the targets of miR-34a could be upregulated by SNHG7, including proliferation-related Notch1, apoptosis-related BCL-2, cell cycle-related CDK6, and EMT-related SMAD4. The oncogene role of SNHG7 in vivo was also confirmed and found that knockdown of SNHG7 delayed the tumor growth with increased miR-34a level and Ki-67 level in OS tissues. These findings demonstrated that the LncRNA SNHG7 is upregulated during the development of OS via inhibition of tumor suppressor miR-34s signals.
长链非编码 RNA(LncRNA)SNHG7(小核 RNA 宿主基因 7)是一种新型的 LncRNA,作为一种癌基因在许多癌症中促进肿瘤增殖并抑制细胞凋亡。然而,SNHG7 在骨肉瘤(OS)中的作用仍有待进一步研究。在本研究中,收集了 30 例 OS 组织和相应的相对正常组织,以确定 OS 中 SNHG7 的表达。结果表明,OS 中高 SNHG7 水平与 Enneking 分期高、远处转移和 OS 患者总生存时间短有关。此外,miR-34a(miR-34a)是一种经典的肿瘤抑制因子。生物信息学分析预测 SNHG7 含有 miR-34a 结合位点,作者发现 SNHG7 在 OS 组织中与 miR-34a 呈负相关,SNHG7 抑制在 OS 细胞系 MG63 和 SaOS2 中诱导 miR-34a 的恢复,导致 miR-34a 介导的肿瘤抑制作用的再激活。肿瘤细胞中 SNHG7 的敲低显著损害细胞活力、迁移和侵袭或 TGF-β 诱导的上皮-间充质转化(EMT),诱导细胞凋亡和 G1/S 期阻滞通过 miR-34a。机制上,miR-34a 的靶基因可以被 SNHG7 上调,包括增殖相关的 Notch1、凋亡相关的 BCL-2、细胞周期相关的 CDK6 和 EMT 相关的 SMAD4。体内 SNHG7 的致癌作用也得到了证实,并发现 SNHG7 的敲低导致 OS 组织中 miR-34a 水平和 Ki-67 水平升高,从而延迟肿瘤生长。这些发现表明,LncRNA SNHG7 通过抑制肿瘤抑制 miR-34s 信号在 OS 的发展过程中上调。
Cancer Biother Radiopharm. 2018-7-10
Cancer Gene Ther. 2025-8-16
Cancers (Basel). 2023-9-26
Curr Issues Mol Biol. 2023-5-15
Biomolecules. 2023-2-20